Aligos Therapeutics Inc (NAS:ALGS)

$ 9.4 0.49 (5.52%) Market Cap: 30.04 Mil Enterprise Value: -56.35 Mil PE Ratio: 0 PB Ratio: 0.44 GF Score: 48/100

Aligos Therapeutics Inc at Jefferies Healthcare Conference Transcript
Jun 08, 2023
Aligos Therapeutics Inc at SVB Securities Global Biopharma Conference (Virtual) Transcript
Feb 15, 2023
Aligos Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 11, 2021
Aligos Therapeutics Inc ALGS Going Public Transcript
Oct 16, 2020

Aligos Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 11, 2021 / 08:40PM GMT

Release Date Price: $781.75 (-1.42%)

Transcript

Eric William Joseph

JPMorgan Chase & Co, Research Division - VP & Senior Analyst

Thanks again for joining us for the annual JPMorgan Healthcare Conference. I'm Eric Joseph, senior biotech analyst at the firm. Our next presenting company is Aligos Therapeutics, and it's my pleasure to welcome and introduce Lawrence Blatt to tell us a little bit about the company.

Just a note before I hand it over, there will be a Q&A session after the presentation. So please do feel free to submit questions via the portal by clicking the Ask a Question button, and I'll ask on your behalf.

With that, Lawrence, thanks again for sharing some of your time with us.

Lawrence M. Blatt

Aligos Therapeutics, Inc. - CEO & Director

Thank you, Eric, and thanks for everybody for coming to this portion of the conference. I will be using the slide deck that is available to you on the JPMorgan website, and I'll call out the slides as I go.

We are Aligos Therapeutics. And if we could move to Slide 3, you can see that our mission for our company is

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.